TY - JOUR
T1 - Induction Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
AU - Miura, Akihiro
AU - Sou, Junichi
AU - Shien, Kazuhiko
AU - Yamamoto, Hiromasa
AU - Toyooka, Shinichi
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The management of locally advanced non-small cell lung cancer (LA-NSCLC) is still controversial, because of complicated patient status and poor prognosis. The purpose of this study was to evaluate the treatment results for induction chemoradiotherapy (iCRT) followed by surgery for LA-NSCLC. From 1999 to 2016, 157 patients were surgically treated after iCRT in our hospital, and their median follow-up was 43 months. Overall survival( OS) was 66.8%, and relapse-free survival( RFS) was 52.0%. The poor prognostic factor in OS by multivariate analysis was lower-lobe origin, incomplete radiotherapy, reoperation, and RFS was lower-lobe origin. The result of our hospital was feasible compared with definitive CRT. The definitive CRT is mainstream for treatment of LA-NSCLC and adjuvant anti-programmed death ligand 1 antibody will influence the treatment strategy, however there are some patients who can get benefit only by iCRT followed by surgery. iCRT followed by surgery is one of the feasible treatment for LA-NSCLC.
AB - The management of locally advanced non-small cell lung cancer (LA-NSCLC) is still controversial, because of complicated patient status and poor prognosis. The purpose of this study was to evaluate the treatment results for induction chemoradiotherapy (iCRT) followed by surgery for LA-NSCLC. From 1999 to 2016, 157 patients were surgically treated after iCRT in our hospital, and their median follow-up was 43 months. Overall survival( OS) was 66.8%, and relapse-free survival( RFS) was 52.0%. The poor prognostic factor in OS by multivariate analysis was lower-lobe origin, incomplete radiotherapy, reoperation, and RFS was lower-lobe origin. The result of our hospital was feasible compared with definitive CRT. The definitive CRT is mainstream for treatment of LA-NSCLC and adjuvant anti-programmed death ligand 1 antibody will influence the treatment strategy, however there are some patients who can get benefit only by iCRT followed by surgery. iCRT followed by surgery is one of the feasible treatment for LA-NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=85063669941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063669941&partnerID=8YFLogxK
M3 - Article
C2 - 29755100
AN - SCOPUS:85063669941
SN - 0021-5252
VL - 71
SP - 270
EP - 277
JO - Kyobu geka. The Japanese journal of thoracic surgery
JF - Kyobu geka. The Japanese journal of thoracic surgery
IS - 4
ER -
